SK16722001A3 - Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce - Google Patents

Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce Download PDF

Info

Publication number
SK16722001A3
SK16722001A3 SK1672-2001A SK16722001A SK16722001A3 SK 16722001 A3 SK16722001 A3 SK 16722001A3 SK 16722001 A SK16722001 A SK 16722001A SK 16722001 A3 SK16722001 A3 SK 16722001A3
Authority
SK
Slovakia
Prior art keywords
radical
formula
radicals
phenyl
carbon atoms
Prior art date
Application number
SK1672-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Jean-Luc Haesslein
Original Assignee
Aventis Pharma S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S. A. filed Critical Aventis Pharma S. A.
Publication of SK16722001A3 publication Critical patent/SK16722001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1672-2001A 1999-05-21 2000-05-18 Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce SK16722001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2000/001335 WO2000071543A1 (fr) 1999-05-21 2000-05-18 Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
SK16722001A3 true SK16722001A3 (sk) 2003-01-09

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1672-2001A SK16722001A3 (sk) 1999-05-21 2000-05-18 Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce

Country Status (33)

Country Link
US (2) US7122669B1 (https=)
EP (1) EP1183256B1 (https=)
JP (1) JP2003500407A (https=)
KR (1) KR100707895B1 (https=)
CN (1) CN1298719C (https=)
AP (1) AP1477A (https=)
AR (1) AR035317A1 (https=)
AT (1) ATE370951T1 (https=)
AU (1) AU4764500A (https=)
BR (1) BR0011282A (https=)
CA (1) CA2374714A1 (https=)
CZ (1) CZ20014163A3 (https=)
DE (1) DE60036102T2 (https=)
DK (1) DK1183256T3 (https=)
DZ (1) DZ3166A1 (https=)
EA (1) EA005072B1 (https=)
ES (1) ES2290033T3 (https=)
FR (1) FR2793794B1 (https=)
HU (1) HUP0201649A3 (https=)
IL (1) IL146441A0 (https=)
MA (1) MA26791A1 (https=)
MX (1) MXPA01011834A (https=)
NO (1) NO20015659L (https=)
NZ (1) NZ515556A (https=)
PL (1) PL352293A1 (https=)
PT (1) PT1183256E (https=)
SK (1) SK16722001A3 (https=)
TR (1) TR200103349T2 (https=)
TW (1) TWI284130B (https=)
UA (1) UA68441C2 (https=)
WO (1) WO2000071543A1 (https=)
YU (1) YU86601A (https=)
ZA (1) ZA200109602B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
DK1377579T3 (da) * 2000-10-31 2009-08-31 Aventis Pharma Inc Acyl- og sulfonylderivater af 6,9-disubstitueret-2(trans-1,4-diaminocyklohexyl)puriner og deres anvendelse som antiproliferative midler
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
EP1556129A4 (en) * 2002-10-15 2011-02-09 Irm Llc COMPOSITIONS AND METHODS OF INDUCING OSTEOGENESIS
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
US10722515B2 (en) * 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
DE69231194T2 (de) * 1991-12-05 2001-02-15 Texas Instruments Inc., Dallas Verfahren zur Verbesserung eines Videosignals
AU658698B2 (en) * 1991-12-06 1995-04-27 Aventis Pharmaceuticals Inc. Novel trans cyclopentanyl purine analogs useful as immunosuppressants
AU7296896A (en) * 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6255485B1 (en) * 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
US7208598B2 (en) 2007-04-24
TWI284130B (en) 2007-07-21
DZ3166A1 (fr) 2000-11-30
WO2000071543A1 (fr) 2000-11-30
CZ20014163A3 (cs) 2002-10-16
NO20015659D0 (no) 2001-11-20
UA68441C2 (en) 2004-08-16
EA005072B1 (ru) 2004-10-28
ATE370951T1 (de) 2007-09-15
ES2290033T3 (es) 2008-02-16
NO20015659L (no) 2002-01-18
FR2793794B1 (fr) 2001-07-27
ZA200109602B (en) 2003-01-29
MA26791A1 (fr) 2004-12-20
EA200101224A1 (ru) 2002-10-31
JP2003500407A (ja) 2003-01-07
YU86601A (sh) 2005-07-19
BR0011282A (pt) 2002-02-26
MXPA01011834A (es) 2002-04-17
US20050187228A1 (en) 2005-08-25
DK1183256T3 (da) 2007-12-03
CA2374714A1 (fr) 2000-11-30
CN1361780A (zh) 2002-07-31
KR20010113975A (ko) 2001-12-28
AU4764500A (en) 2000-12-12
DE60036102T2 (de) 2008-05-15
TR200103349T2 (tr) 2002-05-21
HUP0201649A3 (en) 2003-01-28
DE60036102D1 (de) 2007-10-04
US7122669B1 (en) 2006-10-17
HUP0201649A2 (en) 2002-08-28
EP1183256A1 (fr) 2002-03-06
EP1183256B1 (fr) 2007-08-22
AR035317A1 (es) 2004-05-12
AP1477A (en) 2005-10-19
PL352293A1 (en) 2003-08-11
IL146441A0 (en) 2002-07-25
KR100707895B1 (ko) 2007-04-17
FR2793794A1 (fr) 2000-11-24
NZ515556A (en) 2003-08-29
AP2001002355A0 (en) 2001-12-31
CN1298719C (zh) 2007-02-07
PT1183256E (pt) 2007-11-13

Similar Documents

Publication Publication Date Title
SK16722001A3 (sk) Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce
JP7646632B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
ES2458596T3 (es) Compuestos orgánicos
CA2924206C (en) Pyrimidine fgfr4 inhibitors
TWI548621B (zh) 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
MX2007006821A (es) Derivados de 2,4 (4,6) pirimidina.
HUP0402504A2 (hu) Purinszármazékok, mint purinerg receptor antagonisták
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
AU2018205277B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
ES2693545T3 (es) Compuestos agonistas de GPR142
JP2010526045A (ja) Ｃｄｃ２５ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体
CN105153163A (zh) 2,9-二取代嘌呤-6-氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
TW201536750A (zh) ３，５－二胺基吡唑激酶抑制劑之醫藥上可接受鹽
ES2965684T3 (es) Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CA3025260C (en) Small molecule modulators of pantothenate kinases
CN121362190A (zh) 一种氮-(1-(9h-嘌呤-6-基)哌啶-4-基)苯甲酰胺类化合物、含其的药物组合物及其应用
AU2006202270A1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
US20100173914A1 (en) Pharmaceuticals, compositions and methods of making and using the same
HK40017847A (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases
HK40017847B (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases